Patient Data Highlights Chemotherapy Burden in Endometrial Cancer, Signals Shift in Treatment Preferences
Event summary
- A survey of 119 U.S. endometrial cancer patients revealed 70% consider chemotherapy's burden comparable to the disease itself.
- 71% of surveyed patients expressed a preference against receiving chemotherapy again, and 41% found their second-line chemotherapy worse than the first.
- Findings indicate a desire for more collaborative treatment decision-making, with 91% wanting more information on options beyond chemotherapy.
- The survey, conducted in April 2025, highlights a 'trust gap' among patients of color regarding treatment options and perceived lack of voice.
The big picture
This survey data highlights a growing patient-centricity within oncology, challenging the traditional reliance on chemotherapy as a standard treatment. The findings suggest a potential shift in the market towards less aggressive therapies and a greater emphasis on patient-physician collaboration, which could impact Eisai's oncology portfolio and competitive landscape. The data also underscores the importance of addressing health equity issues in cancer care, particularly within underserved communities.
What we're watching
- Treatment Paradigm
- Eisai and competitors will likely face increasing pressure to develop and promote chemotherapy alternatives for endometrial cancer, given patient preferences for less burdensome treatments.
- Patient Engagement
- The survey underscores the need for improved patient education and shared decision-making processes, which could influence clinical trial recruitment and treatment adherence.
- Health Equity
- The disparity in perceived information access among patients of color suggests a need for targeted outreach and culturally sensitive communication strategies within the oncology space.
Related topics